Moleculin Biotech, Inc.
MBRX· Nasdaq
MBRXMoleculin Biotech, Inc.
Who holds Moleculin Biotech, Inc., from the managers’ Form 13F reports for the quarter ended Jun 30, 2026.
Form 13F covers managers with $100 million or more. Positions are as of the quarter end and filed up to 45 days later; the latest quarter fills in as reports land.
| Manager | Shares | Change | Value | Of portfolio | Filed |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 47.3K | +46.2% | $131.8K | 0% | Aug 12, 2026 |
| Vanguard Capital Management LLC | 42.2K | +204.4% | $117.8K | 0% | Aug 13, 2026 |
| Vanguard Fiduciary Trust Co | 29.9K | +392.1% | $83.4K | 0% | Aug 13, 2026 |
| XTX Topco Ltd | 22.9K | New | $64K | 0.1% | Aug 14, 2026 |
| Morgan Stanley | 20K | +55,555.6% | $55.9K | 0% | Aug 13, 2026 |
| Rockefeller Capital Management L.P. | 15K | +239.3% | $41.9K | 0.1% | Aug 13, 2026 |
| Tower Research Capital LLC (TRC) | 3.5K | +91.5% | $9.8K | 0.1% | Aug 11, 2026 |
| Citigroup Inc | 2.7K | New | $7.5K | 0% | Aug 3, 2026 |
| Barclays PLC | 621 | New | $1.7K | 0% | Aug 14, 2026 |
| BlackRock, Inc. | 491 | ±0% | $1.4K | 0% | Aug 7, 2026 |
| EFG International AG | 434 | ±0% | $1.2K | 0% | Aug 14, 2026 |
| Jones Financial Companies LLLP | 360 | New | $1.2K | 0% | Aug 14, 2026 |
| Wells Fargo & Company | 200 | New | $558 | 0% | Aug 14, 2026 |
| Newbridge Financial Services Group, Inc. | 114 | ±0% | $318 | 0% | Aug 14, 2026 |
| SBI Securities Co., Ltd. | 44 | +2.3% | $123 | 0% | Jul 23, 2026 |
| Danske Bank A/S | 2 | ±0% | $6 | 0% | Aug 10, 2026 |
| CVA Family Office, LLC | 1 | ±0% | $3 | 0% | Aug 7, 2026 |
| Osaic Holdings, Inc. | 1 | ±0% | $2 | 0% | Aug 14, 2026 |
